![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Mylan Announces Third Quarter 2020 Financial Results and Looks Ahead to the Launch of Viatris Inc. PR Newswire HERTFORDSHIRE, England and PITTSBURGH, Nov. 6, 2020 HERTFORDSHIRE, England and...
Mylan Announces Appointment of Experienced Pharmaceutical Executive Bill Szablewski as Head of Capital Markets for Viatris PR Newswire HERTFORDSHIRE, England, and PITTSBURGH, Nov. 2, 2020...
By Maria Armental Pfizer Inc. and Mylan NV have reached a deal with U.S. regulators over the spinoff of Pfizer's off-patent drugs business that requires the sale of several generic drugs to...
Mylan and Pfizer Receive Clearance from the U.S. Federal Trade Commission for Proposed Combination of Mylan and Upjohn Pfizer Announces Record Date for the Proposed Transaction PR...
Pfizer Announces Record Date for the Proposed Transaction Mylan N.V. (NASDAQ: MYL) and Pfizer Inc. (NYSE: PFE) today announced that the U.S. Federal Trade Commission (the “FTC”) accepted a...
Mylan and Development Partner, Synthon, Win Significant European Patent Office Ruling Related to Copaxone® 40mg/mL Decision clears legal pathway to expand access for patients living with multiple...
Mylan and Pfizer Receive European Commission Approval for Proposed Combination of Mylan and Upjohn The Companies Have Also Received Approvals in Australia and New Zealand; Combination on Track to...
Mylan to Present at the Morgan Stanley Virtual 18th Annual Global Healthcare Conference PR Newswire HERTFORDSHIRE, England and PITTSBURGH, Sept. 9, 2020 HERTFORDSHIRE, England and PITTSBURGH...
Mylan to Present at the BofA Securities Virtual Global Healthcare Conference PR Newswire HERTFORDSHIRE, England and PITTSBURGH, Sept. 9, 2020 HERTFORDSHIRE, England and PITTSBURGH, Sept. 9, 2020...
Mylan to Acquire Aspen's Thrombosis Business in Europe Acquisition further complements and expands Mylan's complex injectables offering and presence in hospitals Transaction expected to be...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions